ECTRIMS 2025 – Late Breaking Abstracts

The late breaking abstract submission for ECTRIMS 2025 is now closed. Thanks to all for their submissions! Notification of acceptance or rejection of submitted Late Breaking abstracts will be sent to the corresponding authors via email in July 2025. Full instructions concerning preparation and presentation will be included. 

A selected number of late breaking abstracts will be accepted for oral presentation during the Late Breaking Session on Friday, 26 September 2025. The remaining accepted abstracts will be presented as a poster. Each abstract will be reviewed by at least three members of the Scientific Programme Committee. The presenting author of an accepted Late Breaking abstract must register and attend the congress.

1. Abstracts may only be submitted online. Abstracts submitted by fax or email will not be accepted.
2. Abstracts must be submitted in English. Please use UK English spelling.
3. The presenting author of an accepted abstract must register and attend the congress.
4. If your abstract has been accepted as poster presentation, you will be asked to prepare a poster in paper and electronic format (ePoster).If your abstract has been accepted as an ePoster only, you will be asked to prepare just an electronic format (ePoster). Guidelines will follow based on acceptance of your abstract. Presenting authors of a paper poster presentation will present their posters in sessions during the congress.
5. Abstracts should contain only original material not published or presented elsewhere prior to 23 September 2025.
6. Provide a short specific title indicating the nature of the investigation. The introduction and objectives/aims of the study should appear clearly to the reader. The methods and results must contain data, and the conclusions should be clearly expressed.
7. The title may not exceed 250 characters including spaces. The abstract text may not be longer than 2556 characters (approx. 300 words) including headlines and spaces, excluding disclosures.
8. All abbreviations must be defined the first time they appear in your text (but, do not define in the title). Example: Multiple Sclerosis Impact Scale (MSIS), before being used as an abbreviation only.
9. Use generic drug names.
10. Do not include tables, charts or other graphics. These will be deleted by the editors.
11. Authors should indicate their presentation type preference:
    – oral or poster presentation
    – poster presentation only
    Note: “poster presentation only” implies that your abstract will be considered for poster presentation only.
    The Scientific Programme Committee reserves the right to decide on the final allocation and presentation method. Kindly note that an author may only give a maximum of 1 oral presentation that have been selected through submitted abstracts. In case an author has more than 1 oral abstract presentations, the person will be contacted to discuss which abstract will be presented by the author and who will present the other presentation(s) from the list of co-authors. If none of the co-authors can present the abstract, the abstract will no longer be considered for oral presentation.
12. A selected number of abstracts will be accepted for oral presentation based on their scientific merits and on their relation to the topics addressed in the scientific programme of the Congress. We therefore encourage submissions on the main topics covered in the scientific programme.
13. Disclosure of potential conflict of interest (e.g. grant support, consultancy, membership on advisory councils, speaker’s bureau) by all authors and source of funding are mandatory. Each listed author should prepare a one sentence statement that will be published with the abstract. All disclosures should be listed for the last 3 years.
14. Abstracts from commercial entities will be considered. However, abstracts reporting results from collaborative research conducted by independent (non-company) investigators and investigators who are employees of commercial entities will not be accepted unless the independent (academic, clinician and/or scientist) investigators are included as authors. Abstract may not be presented unless the independent investigator is the presenting author.
15. Please make sure to state your correct e-mail address. After having submitted your abstract, you will receive a confirmation by e-mail with the following information:
    – pdf of your submitted abstract
    – your abstract number (to be uses as reference for correspondence and questions that might arise)
    If you do not receive a confirmation by e-mail, please contact ectrims.abstracts@congrex.com
16. Should you wish to make corrections to an abstract already submitted or if you wish to submit other abstracts later, you may use your personal access code. This will shorten the submission procedure.
    Corrections to abstracts can only be made up to the deadline of 3 June 2025, 23:59 CEST.
17. We kindly ask you to upload a picture of the presenting author to your account. Please upload a photo in JPG or GIF format and with a max. size of 1 MB.

All accepted abstracts will be published in the online supplement of the Multiple Sclerosis Journal, as well as on the ECTRIMS 2025 Congress website. The full text of late-breaking abstracts will be published on the first day of the congress (Wednesday, 24 September 2025, at 08:00 CEST) on the congress website.

A selected number of Late Breaking Abstracts will be accepted for oral presentation during the Late Breaking Session on Friday, 26 September 2025 from 10:30 to 12:00 CEST. The remaining accepted abstracts will be presented as paper poster presentation or ePoster only.

Each abstract will be reviewed by at least three external experts and final selection will be made by the Scientific Programme Committee. Notification of acceptance or rejection of submitted abstracts will be sent to the corresponding authors via email in July 2025. Full instructions concerning preparation and presentation will be included.